Nouscom
Nouscom • Re-defining innovation
Rome, Italy · Founded 2015 · $82.0M raised
- Headquarters
- Rome
- Employees
- 11–50
- Founded
- 2015
- Business Model
- B2B
- Website
- nouscom.com
- Total Funding
- $82.0M
- Last Round
- $82.0M Series CMar 2024
- Rounds
- 1
About
Nouscom is a clinical-stage immuno-oncology company developing next-generation viral vector cancer vaccines based on neoantigens. Founded in 2015, the company's proprietary platform uses recombinant adenoviruses derived from non-human great apes (GAd) and MVA to generate potent anti-tumor immune responses, enabling both off-the-shelf and personalized cancer immunotherapies. Nouscom is headquartered in Basel, Switzerland, with research operations in Rome, Italy.
Summary
Nouscom is a Biotech company based in Rome, Italy, founded in 2015. It has raised $82.0M in total across 1 round, most recently a $82.0M Series C round in Mar 2024. Investors include Angelini Ventures.
Tech & App Stack
7 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Mar 2024
Investors
Similar Companies
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company